Dr Montalbán Bravo speaks with ecancertv at ASH 2016 about two promising clinical studies for the treatment of haematological disorders with guadecitabine, and azacitadine plus vorinostat.

He begins with a preliminary report on an ongoing phase II, single arm trial of guadecitabine against myelodysplastic syndrome and chronic myelomonocytic leukaemia, in which he notes high levels of response and low-grade toxicity, and introduces multi-centre studies also recruiting patients.

Dr Montalbán Bravo also discusses azacitadine combined with vorinostat as a treatment for patients with poor performance status, and that a majority of those treated experienced a prolonged survival past the median of 60 days.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.